CO2022011685A2 - Vacunas de arn contra el coronavirus - Google Patents

Vacunas de arn contra el coronavirus

Info

Publication number
CO2022011685A2
CO2022011685A2 CONC2022/0011685A CO2022011685A CO2022011685A2 CO 2022011685 A2 CO2022011685 A2 CO 2022011685A2 CO 2022011685 A CO2022011685 A CO 2022011685A CO 2022011685 A2 CO2022011685 A2 CO 2022011685A2
Authority
CO
Colombia
Prior art keywords
vaccines against
rna vaccines
against coronavirus
vaccines
coronavirus
Prior art date
Application number
CONC2022/0011685A
Other languages
English (en)
Inventor
Guillaume Stewart-Jones
Elisabeth Narayanan
Hamilton Bennett
Andrea Carfi
Mihir Metkar
Vladimir Presnyak
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of CO2022011685A2 publication Critical patent/CO2022011685A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La descripción se refiere a vacunas de ácido ribonucleico (ARN) contra el coronavirus, así como a métodos de uso de las vacunas y composiciones que comprenden las vacunas.
CONC2022/0011685A 2020-01-28 2022-08-19 Vacunas de arn contra el coronavirus CO2022011685A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062967006P 2020-01-28 2020-01-28
US202062971825P 2020-02-07 2020-02-07
US202063002094P 2020-03-30 2020-03-30
US202063009005P 2020-04-13 2020-04-13
US202063016175P 2020-04-27 2020-04-27
PCT/US2021/015145 WO2021154763A1 (en) 2020-01-28 2021-01-26 Coronavirus rna vaccines

Publications (1)

Publication Number Publication Date
CO2022011685A2 true CO2022011685A2 (es) 2022-08-30

Family

ID=74669543

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0011685A CO2022011685A2 (es) 2020-01-28 2022-08-19 Vacunas de arn contra el coronavirus

Country Status (15)

Country Link
US (1) US20230108894A1 (es)
EP (1) EP4096710A1 (es)
JP (1) JP2023511633A (es)
KR (1) KR20220133224A (es)
CN (1) CN115175698A (es)
AU (1) AU2021213108A1 (es)
BR (1) BR112022014837A2 (es)
CA (1) CA3168902A1 (es)
CO (1) CO2022011685A2 (es)
DO (1) DOP2022000152A (es)
IL (1) IL295016A (es)
MX (1) MX2022009280A (es)
PE (1) PE20221756A1 (es)
TW (1) TW202142556A (es)
WO (1) WO2021154763A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20230075527A1 (en) * 2020-01-31 2023-03-09 Janssen Pharmaceuticals, Inc Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
US20240277830A1 (en) 2020-02-04 2024-08-22 CureVac SE Coronavirus vaccine
CA3160511A1 (en) 2020-02-04 2021-08-12 Susanne RAUCH Coronavirus vaccine
US20240269266A1 (en) * 2020-04-14 2024-08-15 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
GB2594364A (en) 2020-04-22 2021-10-27 Biontech Rna Pharmaceuticals Gmbh Coronavirus vaccine
WO2021159130A2 (en) * 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
TW202237148A (zh) * 2020-11-16 2022-10-01 德商拜恩迪克公司 包含rna之lnp組合物以及製備、儲存及使用彼之方法
WO2022218503A1 (en) * 2021-04-12 2022-10-20 BioNTech SE Lnp compositions comprising rna and methods for preparing, storing and using the same
KR20230164648A (ko) 2020-12-22 2023-12-04 큐어백 에스이 SARS-CoV-2 변이체에 대한 RNA 백신
CN118109489A (zh) * 2020-12-31 2024-05-31 四川大学华西医院 编码新型冠状病毒的结构蛋白的核酸分子及其疫苗的应用
WO2022155524A1 (en) * 2021-01-15 2022-07-21 Modernatx, Inc. Variant strain-based coronavirus vaccines
EP4277653A1 (en) * 2021-01-15 2023-11-22 ModernaTX, Inc. Variant strain-based coronavirus vaccines
US20220356212A1 (en) * 2021-03-26 2022-11-10 Nanogen Pharmaceutical Biotechnology JSC Modified spike protein and method of treatment
EP4319803A1 (en) * 2021-04-08 2024-02-14 Vaxthera SAS Coronavirus vaccine comprising a mosaic protein
WO2022232648A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion-stabilized lassa virus glycoprotein complex and its use
AU2022271249A1 (en) 2021-05-04 2023-11-16 BioNTech SE Immunogen selection
CN115594742A (zh) * 2021-07-09 2023-01-13 复旦大学（Cn） 一种冠状病毒s蛋白变体及其应用
CA3235867A1 (en) 2021-10-22 2023-04-27 Munir MOSAHEB Mrna vaccine composition
WO2023086961A1 (en) 2021-11-12 2023-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 spike fused to a hepatitis b surface antigen
CN118488834A (zh) 2021-11-23 2024-08-13 赛欧生物医药股份有限公司 细菌源性脂质组合物和其用途
IL313254A (en) * 2021-11-30 2024-08-01 Novavax Inc Vaccine formulations against corona
AR127858A1 (es) * 2021-12-03 2024-03-06 Suzhou Abogen Biosciences Co Ltd VACUNAS DE ÁCIDOS NUCLEICOS PARA EL CORONAVIRUS BASADAS EN SECUENCIAS DERIVADAS DE LA CEPA ÓMICRON DEL SARS-CoV-2
KR20230095025A (ko) * 2021-12-20 2023-06-28 아이진 주식회사 변이 SARS-CoV-2 백신 조성물 및 이의 용도
WO2023122080A1 (en) 2021-12-20 2023-06-29 Senda Biosciences, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
WO2023121131A1 (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 코로나바이러스 백신
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
TW202345863A (zh) * 2022-02-09 2023-12-01 美商現代公司 黏膜投與方法及調配物
CN114404584B (zh) * 2022-04-01 2022-07-26 康希诺生物股份公司 一种新型冠状病毒mRNA疫苗及其制备方法和用途
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
TW202406929A (zh) 2022-05-05 2024-02-16 比利時商ｅＴｈｅＲＮＡ免疫治療公司 多表位構築體
WO2023220645A1 (en) 2022-05-10 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccine for human t-lymphotropic virus-1
WO2023250111A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
US11654121B1 (en) 2022-06-22 2023-05-23 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024014770A1 (ko) * 2022-07-14 2024-01-18 엠큐렉스 주식회사 mRNA 백신 및 치료제의 제조를 위한 변형된 RNA
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
WO2024159172A1 (en) 2023-01-27 2024-08-02 Senda Biosciences, Inc. A modified lipid composition and uses thereof
CN117886903A (zh) * 2023-03-03 2024-04-16 上海蓝鹊生物医药有限公司 一种抗新冠病毒的蛋白或mRNA疫苗及其制备方法和应用
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
EP1832603B1 (de) 2001-06-05 2010-02-03 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
AU2008271907A1 (en) 2007-06-29 2009-01-08 Commonwealth Scientific And Industrial Research Organisation Methods for degrading toxic compounds
AU2008304201C1 (en) 2007-09-26 2015-02-05 Intrexon Corporation Synthetic 5'UTRs, expression vectors, and methods for increasing transgene expression
EP2610341B1 (en) 2007-12-11 2014-09-17 The Scripps Research Institute Compositions and methods related to mRNA translational enhancer elements
EP2459231B1 (de) 2009-07-31 2016-06-08 Ethris Gmbh Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
JP6184945B2 (ja) 2011-06-08 2017-08-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法
ES2864878T5 (es) 2012-06-08 2024-10-23 Translate Bio Inc Administración pulmonar de ARN, a células objetivo no pulmonares
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
RS62565B1 (sr) 2013-03-14 2021-12-31 Translate Bio Inc Metode i kompozicije za isporuku antitela kodiranih od strane irnk
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
ES2670529T3 (es) 2013-03-15 2018-05-30 Translate Bio, Inc. Mejora sinergística de la entrega de ácidos nucleicos a través de formulaciones mezcladas
MX2016002152A (es) 2013-08-21 2017-01-05 Curevac Ag Metodo para aumentar la expresion de proteinas codificadas por arn.
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
JP6704850B2 (ja) 2013-12-30 2020-06-03 キュアバック アーゲー 人工核酸分子
KR101793271B1 (ko) 2015-07-09 2017-11-20 인텔렉추얼디스커버리 주식회사 공기압을 이용한 휴대용 살균수 스프레이건
EP3364983A4 (en) * 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST RESPIRATORY VIRUS
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
MX2019002904A (es) 2016-09-14 2019-09-26 Modernatx Inc Composiciones de arn de alta pureza y métodos para su preparación.
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
CN111212905A (zh) 2017-08-18 2020-05-29 摩登纳特斯有限公司 Rna聚合酶变体

Also Published As

Publication number Publication date
DOP2022000152A (es) 2022-10-31
KR20220133224A (ko) 2022-10-04
WO2021154763A1 (en) 2021-08-05
MX2022009280A (es) 2022-08-16
AU2021213108A1 (en) 2022-08-18
CA3168902A1 (en) 2021-08-05
EP4096710A1 (en) 2022-12-07
BR112022014837A2 (pt) 2022-09-27
CN115175698A (zh) 2022-10-11
TW202142556A (zh) 2021-11-16
IL295016A (en) 2022-09-01
JP2023511633A (ja) 2023-03-20
PE20221756A1 (es) 2022-11-11
US20230108894A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
CO2022011685A2 (es) Vacunas de arn contra el coronavirus
WO2021159130A3 (en) Coronavirus rna vaccines and methods of use
CL2018001053A1 (es) Vacuna contra el virus sincicial respiratorio
CL2018001056A1 (es) Vacuna contra el virus herpes simplex
WO2021155243A8 (en) Respiratory virus immunizing compositions
BR112022015565A2 (pt) Vacinas de domínio de mrna para sars-cov-2
MD3718565T2 (ro) Vaccinuri împotriva virusului respirator
WO2023283642A3 (en) Pan-human coronavirus concatemeric vaccines
CO2022009538A2 (es) Arn guía antisentido con región funcional añadida para editar arn blanco
WO2022221359A8 (en) Epstein-barr virus mrna vaccines
AR050972A1 (es) Microarn
AR069883A1 (es) Virus de la estomatitis vesicular geneticamente modificado, composicion inmunogenica que lo comprende, metodo para producirlo, metodos para adaptar un virus para crecer en el cultivo de cedula y para proteger un mamifero contra la infeccion con un organismo patogeno
UY37179A (es) Composiciones producidas por microorganismos con actividad estimuladora sobre las plantas
AR065100A1 (es) Plantas con rasgos relacionados con el rendimiento mejorado y un metodo para producirlas
BR112015000520A2 (pt) agente de espessamento estável com lipase
CL2011000583A1 (es) Composicion plaguicida que comprende un derivado del ácido alfa-alcoxifenil-acetico y un compuesto neonicotenoide.
CO2023015036A2 (es) Composición inmunogénica contra la influenza
CY1116142T1 (el) Εισπνεομενο φαρμακο που περιλαμβανει τιοτροπιο
CU20170108A7 (es) Composición ácida a base de leonardita y aminoácidos
MX2022006748A (es) Composiciones de acidos nucleicos.
AR121205A1 (es) Vacunas de arn contra el coronavirus
MX2022012561A (es) Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).
AR065847A1 (es) Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso.
MX2023014976A (es) Composiciones y metodos para silenciar la expresion de miocilina (myoc).
CL2011001097A1 (es) Composicion de vacuna que comprende e. meleagrimitis 2 y meleagrimitis 1; uso de dicha vacuna para inmunizar un pavo contra la cocciodiosis; metodo para identificar un aislado de eimeria como una eimeria meleagrimitis 2; y kit de amplificacion por pcr.